KR102627084B1 - 대사성 질환을 치료하기 위한 조성물 및 방법 - Google Patents

대사성 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102627084B1
KR102627084B1 KR1020187037955A KR20187037955A KR102627084B1 KR 102627084 B1 KR102627084 B1 KR 102627084B1 KR 1020187037955 A KR1020187037955 A KR 1020187037955A KR 20187037955 A KR20187037955 A KR 20187037955A KR 102627084 B1 KR102627084 B1 KR 102627084B1
Authority
KR
South Korea
Prior art keywords
delete delete
polypeptide
cmyr
serum
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037955A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015392A (ko
Inventor
홍리 리우
Original Assignee
상하이 헵 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 헵 파마수티컬 컴퍼니 리미티드 filed Critical 상하이 헵 파마수티컬 컴퍼니 리미티드
Publication of KR20190015392A publication Critical patent/KR20190015392A/ko
Application granted granted Critical
Publication of KR102627084B1 publication Critical patent/KR102627084B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020187037955A 2016-05-30 2017-05-31 대사성 질환을 치료하기 위한 조성물 및 방법 Active KR102627084B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610370442.4 2016-05-30
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (2)

Publication Number Publication Date
KR20190015392A KR20190015392A (ko) 2019-02-13
KR102627084B1 true KR102627084B1 (ko) 2024-01-19

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187037955A Active KR102627084B1 (ko) 2016-05-30 2017-05-31 대사성 질환을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (2) US11633454B2 (https=)
EP (1) EP3463422B1 (https=)
JP (1) JP7684788B2 (https=)
KR (1) KR102627084B1 (https=)
CN (1) CN109310737B (https=)
AU (1) AU2017274094B2 (https=)
CA (1) CA3026140A1 (https=)
DK (1) DK3463422T3 (https=)
ES (1) ES2979305T3 (https=)
WO (1) WO2017206898A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022145711A1 (ko) * 2020-12-28 2022-07-07 주식회사 엠디헬스케어 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 대사질환 예방 또는 치료용 조성물
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072524A1 (en) * 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2016055534A2 (en) * 2014-10-07 2016-04-14 Myr Gmbh Combination therapy of hbv and hdv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN104130316B (zh) * 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
EP3189850A1 (en) * 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072524A1 (en) * 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2016055534A2 (en) * 2014-10-07 2016-04-14 Myr Gmbh Combination therapy of hbv and hdv infection

Also Published As

Publication number Publication date
AU2017274094B2 (en) 2020-09-10
AU2017274094A1 (en) 2019-02-14
CN109310737B (zh) 2023-05-05
US20230414706A1 (en) 2023-12-28
EP3463422A1 (en) 2019-04-10
EP3463422A4 (en) 2020-02-26
KR20190015392A (ko) 2019-02-13
US20200323951A1 (en) 2020-10-15
DK3463422T3 (da) 2024-07-22
ES2979305T3 (es) 2024-09-25
US11633454B2 (en) 2023-04-25
JP7684788B2 (ja) 2025-05-28
JP2019520341A (ja) 2019-07-18
CA3026140A1 (en) 2017-12-07
EP3463422B1 (en) 2024-05-22
WO2017206898A1 (en) 2017-12-07
CN109310737A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
CN111225680B (zh) 非酒精性脂肪性肝病的治疗药物
AU2015276203B2 (en) Exendin-4 derivatives as selective glucagon receptor agonists
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
US20250312420A1 (en) Methods and compositions for treating hypoglycemic disorders
JP5485876B2 (ja) 代謝疾患の治療における治療剤としての非アシル化グレリン
CA2230968A1 (en) Method of treating insulin resistance
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
KR20250067161A (ko) Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
JP6031121B2 (ja) 非アシル化グレリンを使用したグレリンレベル及びグレリン／非アシル化グレリン比の調節
Ladenheim et al. Caudal hindbrain neuromedin B-preferring receptors participate in the control of food intake
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
WO2014011908A1 (en) Apolipoprotein mixtures
WO2008062420A2 (en) Use of glucagon and insulin in methods and compositions for the treatment of acute brain injury and neurodegenerative disorders
CN121285380A (zh) 糖尿病的治疗
Kiriyama et al. Stimulatory effects of bombesin on plasma trypsin release and exocrine pancreatic secretion in dogs
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601